Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Spine implant safety under the microscope: 1,050 patients enrolled

NCT ID NCT04418830

Disease control Sponsor: NuVasive Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 1,050 adults who are getting NuVasive interbody implants during spine surgery for conditions like degenerative disc disease or spinal stenosis. Researchers are monitoring complications, bone fusion, and patient-reported pain relief over 24 months. The goal is to better understand the implants' safety and long-term performance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NuVasive interbody implants (medical device)
What this could lead to
If successful, this study could confirm that these implants are safe and effective for treating degenerative spine conditions, helping guide future surgical decisions.
What could go wrong
This is an observational study, not a randomized trial, so results may not prove superiority over other treatments. Complications like implant failure or non-fusion are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,050 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The Enrolled Population will include all subjects who meet the criteria for enrollment, specifically, those subjects who: * Satisfied the inclusion and exclusion criteria * Signed the informed consent * Underwent the surgical procedure, as defined in this protocol Subjects not meeting any of these criteria will not be considered enrolled in the study, and therefore not included in any study population or analysis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who are ≥18 years of age at the time of consent 2. Planned spine surgery using interbody implants at: 1. One or two adjacent thoracic, lumbar, and/or lumbosacral levels for degenerative disc disease or degenerative spondylolisthesis, or 2. One or two adjacent thoracic, lumbar, and/or lumbosacral levels for spinal stenosis (not applicable for MLX, TLX, or XLX ACR), or 3. Any number of thoracic, lumbar, and/or lumbosacral levels for degenerative scoliosis (defined as \>10º coronal curve), or 4. Any number of thoracic, lumbar, and/or lumbosacral levels for sagittal deformity (not applicable for MLX, TLX, or XLX ACR). 3. Use of one of the following implants (NuVasive, Inc., San Diego, CA): 1. Base Interfixated 2. Brigade Interfixated 3. Coalesce Thoracolumbar 4. Cohere TLIF 5. Cohere XLIF 6. Coroent Ti PLIF 7. Coroent Ti TLIF 8. Coroent Ti XLIF 9. MLX 10. Modulus ALIF 11. Modulus TLIF 12. Modulus XLIF 13. TLX 14. XLX ACR 4. Interbody fusion with one or more of the following (as allowed by implant type): 1. autograft 2. allograft (i.e., cancellous and/or corticocancellous allograft bone) 3. Attrax Putty (NuVasive) (not applicable for MLX, TLX, or XLX ACR) 5. NuVasive supplemental internal fixation cleared by the applicable regulatory body for use in the thoracolumbar spine (unless the interbody device to be used is interfixated and is cleared by the regulatory body to be used standalone) 6. Able to undergo surgery based on physical exam, medical history, and surgeon judgment 7. Understands the conditions of enrollment, is willing to follow medical advice including postoperative activity restrictions per the surgeon's standard of care, and is willing to sign an informed consent form to participate in the study Exclusion Criteria: 1. Use of any bone graft that is not cleared by the applicable regulatory body for use within interbody implants. Examples of these include: 1. Bone morphogenetic protein (BMP) (e.g., Infuse (Medtronic)) 2. Synthetic bone graft extenders (e.g., Attrax Scaffold (NuVasive), Formagraft (NuVasive), Mastergraft (Medtronic), Vitoss (Stryker), Actifuse (Baxter), nanOss (RTI Surgical), Fibergraft (Prosidyan/Depuy Synthes), ChronOs (Depuy Synthes)) 3. Demineralized bone matrices (DBM) regulated as medical devices by the FDA (e.g., Grafton Putty/Gel (Medtronic), DBX (MTF/Depuy Synthes), Accell Evo3 (IsoTis), Propel Putty/Gel (NuVasive)) 4. Peptide enhanced bone graft (e.g., iFactor (Cerapedics)) 2. Previous lumbar fusion surgery at the level(s) to be treated (adjacent level surgery is acceptable; prior decompression is acceptable) 3. Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) 4. Use of bone growth stimulators postoperatively 5. Active smoking within 6 weeks before surgery 6. Patient has known sensitivity to the materials implanted 7. Systemic or local infection (latent or active) or signs of local inflammation 8. Patient has inadequate bone stock or bone quality, or a physical or medical condition that would prohibit beneficial surgical outcomes based on surgeon judgment 9. Patient is a prisoner 10. Patient is participating in another clinical study that would confound study data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative disc disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atlantic Brain and Spine

    Wilmington, North Carolina, 28401, United States

  • Beaumont Hospital Research Institute

    Royal Oak, Michigan, 48073, United States

  • Columbia Orthopaedics Group

    Columbia, Missouri, 65201, United States

  • DuPage Medical Group

    Naperville, Illinois, 60540, United States

  • Duke University

    Durham, North Carolina, 27710, United States

  • Hartford Healthcare Bone and Joint Institute

    Hartford, Connecticut, 06106, United States

  • Hoag Orthopedics

    Orange, California, 92868, United States

  • Lyerly Neurosurgery

    Jacksonville, Florida, 32207, United States

  • Northwestern University

    Chicago, Illinois, 60610, United States

  • Ohio State University

    Dublin, Ohio, 43016, United States

  • Summa Health

    Akron, Ohio, 44320, United States

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania, 15213, United States

  • University of California San Diego

    La Jolla, California, 92037, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

  • Valley Spine Care

    Merced, California, 95348, United States

  • Verma Spine

    Los Alamitos, California, 90720, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.